Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Provencher

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumorsIsabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
Gynecologic Oncology|May 7, 2011
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer studyThomas J Herzog, Jan B Vermorken, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervixToyomi Satoh, Yuji Takei, Isabelle Treilleux, et al.
Cancers|August 14, 2020
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the DiseaseSkye Alexandre Sauriol, Kayla Simeone, Lise Portelance, et al.
Oncogene|August 16, 2006
Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3pN A L Cody, V Ouellet, E N Manderson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 10, 2012
Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutationDiala Abd-Rabbo, Christine Abaji, Guillaume B Cardin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinomaSatoru Sagae, Nobuyuki Susumu, Akila N Viswanathan, et al.
Gynecologic Oncology|January 29, 2023
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancerT M Davidson, C L Lebreton, A E Wahner Hendricksen, et al.
Plos One|October 3, 2012
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcomePaulina M Wojnarowicz, Kathleen Klein Oros, Michael C J Quinn, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumorsIsabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
Gynecologic Oncology|May 7, 2011
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer studyThomas J Herzog, Jan B Vermorken, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervixToyomi Satoh, Yuji Takei, Isabelle Treilleux, et al.
Cancers|August 14, 2020
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the DiseaseSkye Alexandre Sauriol, Kayla Simeone, Lise Portelance, et al.
Oncogene|August 16, 2006
Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3pN A L Cody, V Ouellet, E N Manderson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 10, 2012
Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutationDiala Abd-Rabbo, Christine Abaji, Guillaume B Cardin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinomaSatoru Sagae, Nobuyuki Susumu, Akila N Viswanathan, et al.
Gynecologic Oncology|January 29, 2023
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancerT M Davidson, C L Lebreton, A E Wahner Hendricksen, et al.
Plos One|October 3, 2012
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcomePaulina M Wojnarowicz, Kathleen Klein Oros, Michael C J Quinn, et al.
Pageof 11